Non-invasive predictive biomarkers for preclinical Alzheimer’s disease (AD) may inform future dementia risk and support early intervention for AD. In this review, we describe clinical, biomarker and neuropathologic characteristics in spontaneously aged Old World monkeys (OWMs) in the context of preclinical AD. Reliable age-related amyloid-β (Aβ) plaque deposition occurs in OWMs. Plaque composition is complex, signifying significant disruption of synaptic connectivity. Pretangle pTau pathology in brainstem nuclei and limbic system prevails, consistent with Braak Stage 1b in macaques. Soluble pTau distribution approximates Braak Stage III-IV stage in perfused frozen macaque tissue, and colocalizes with Aβ and acetylcholinesterase labeling in AD-vulnerable circuits. Tau and Aβ pathology in OWMs is accompanied by fluid biomarker changes consistent with Core 1 AD diagnosis in humans but cannot be visualized using amyloid or tau tracers. Despite age-related cognitive decline, aging OWMs do not experience significant hippocampal atrophy or neuropathologic co-morbidities. Minimal expression of senescence markers implicates differences in rates of biological brain aging between OWMs and humans. OWMs support mechanistic studies and biomarker discovery in the areas of Aβ plaque and pTau evolution and resolution following anti-amyloid or Tau-directed therapeutics, as well as effects of senotherapeutics, lifestyle intervention or co-morbidities on biological brain aging.
A blood test for Alzheimer’s disease. Med Lett Drugs Ther. 2025;67(1732):109. doi:10.58347/tml.2025.1732b.
2.
AbdelhakAFoschiMAbu-RumeilehS, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158-172. doi:10.1038/s41582-021-00616-3.
3.
AffleckAJSachdevPSHallidayGM.Past antihypertensive medication use is associated with lower levels of small vessel disease and lower Aβ plaque stage in the brains of older individuals. Neuropathol Appl Neurobiol. 2023;49(4):e12922. doi:10.1111/nan.12922.
4.
AgueroCDhaynautMAmaralAC, et al. Head-to-head comparison of [(18)F]-Flortaucipir, [(18)F]-MK-6240 and [(18)F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases. Acta Neuropathol. 2024;147(1):25. doi:10.1007/s00401-023-02672-z.
5.
AgueroCDhaynautMNormandinMD, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7(1):37. doi:10.1186/s40478-019-0686-6.
6.
ArnstenAFTDattaDPreussTM. Studies of aging nonhuman primates illuminate the etiology of early-stage Alzheimer’s-like neuropathology: an evolutionary perspective. Am J Primatol. 2021;83(11):e23254. doi:10.1002/ajp.23254.
7.
BarnesCAPermenterMRVogtJAChenKBeachTG.Human Alzheimer’s disease ATN/ABC staging applied to aging rhesus macaque brains: association with cognition and MRI-based regional gray matter volume. J Comp Neurol. 2024;532(9):e25670. doi:10.1002/cne.25670.
8.
BarthélemyNRBatemanRJHirtzC, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020;12(1):26. doi:10.1186/s13195-020-00596-4.
9.
BarthélemyNRSaefBLiY, et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease. Nat Aging. 2023;3(4):391-401. doi:10.1038/s43587-023-00380-7.
10.
BartusRTDeanRL 3rdFlemingDL.Aging in the rhesus monkey: effects on visual discrimination learning and reversal learning. J Gerontol. 1979;34(2):209-219. doi:10.1093/geronj/34.2.209.
11.
BathlaSDattaDBolatD, et al. Dysregulated calcium signaling in the aged macaque entorhinal cortex associated with tau hyperphosphorylation. Front Aging Neurosci. 2025;17:1549770.
12.
BeckmanDOttSDonis-CoxK, et al. Oligomeric Aβ in the monkey brain impacts synaptic integrity and induces accelerated cortical aging. Proc Natl Acad Sci USA. 2019;116(52):26239-26246. doi:10.1073/pnas.1902301116.
13.
BenedetALMilà-AlomàMVrillonA, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471-1483. doi:10.1001/jamaneurol.2021.3671.
14.
BersonEFryeBMGajeraCR, et al. Mediterranean vs. Western diet effects on the primate cerebral cortical pre-synaptic proteome: relationships with the transcriptome and multi-system phenotypes. Alzheimers Dement. 2025;21(3):e70041. doi:10.1002/alz.70041.
15.
BobinskiMde LeonMJWegielJ, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience. 2000;95(3):721-725. doi:10.1016/s0306-4522(99)00476-5.
16.
BraakEBraakHMandelkowEM.A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 1994;87(6):554-567. doi:10.1007/bf00293315.
17.
BraakHAlafuzoffIArzbergerTKretzschmarHDel TrediciK.Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389-404. doi:10.1007/s00401-006-0127-z.
18.
BraakHBraakE.Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271-278. doi:10.1016/0197-4580(95)00021-6.
19.
BraakHDel TrediciK.The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol. 2011;121(2):171-181. doi:10.1007/s00401-010-0789-4.
20.
BraakHThalDRGhebremedhinEDel TrediciK.Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960-969. doi:10.1097/NEN.0b013e318232a379.
21.
BrenowitzWDKeeneCDHawesSE, et al. Alzheimer’s disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. Neurobiol Aging. 2017;53:83-92. doi:10.1016/j.neurobiolaging.2017.01.017.
22.
BurkeSNWallaceJLHartzellALNematollahiSPlangeKBarnesCA.Age-associated deficits in pattern separation functions of the perirhinal cortex: a cross-species consensus. Behav Neurosci. 2011;125(6):836-847. doi:10.1037/a0026238.
23.
ChatterjeePPedriniSDoeckeJD, et al. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer’s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement. 2023;19(4):1117-1134. doi:10.1002/alz.12724.
24.
CohenADKlunkWE.Early detection of Alzheimer’s disease using PiB and FDG PET. Neurobiol Dis. 2014;72, pt A:117-122. doi:10.1016/j.nbd.2014.05.001.
25.
Concha-MarambioLPritzkowSShahnawazMFarrisCMSotoC.Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat Protoc. 2023;18(4):1179-1196. doi:10.1038/s41596-022-00787-3.
26.
CoreyTMIllanesOLawrenceMPerezSELiddieSCallananJJ.Naturally occurring histological findings and Alzheimer’s-like pathology in the brain of aging African green monkeys (Chlorocebus sabaeus). J Comp Neurol. 2023;531(13):1276-1298. doi:10.1002/cne.25494.
27.
CramerPEGentzelRCTanisKQ, et al. Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer’s disease. Neurobiol Aging. 2018;64:92-106. doi:10.1016/j.neurobiolaging.2017.12.011.
28.
CurtisCGamezJESinghU, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72(3):287-294. doi:10.1001/jamaneurol.2014.4144.
29.
DahlénADRoshanbinSAguilarX, et al. PET imaging of TREM2 in amyloid-beta induced neuroinflammation. Eur J Nucl Med Mol Imaging. 2025;52(11):4320-4333. doi:10.1007/s00259-025-07358-0.
30.
DakterzadaFLópez-OrtegaRVilella-FiguerolaA, et al. Performance of plasma phosphorylated tau-217 in patients on the continuum of Alzheimer’s disease. Int J Mol Sci. 2025;26(14):6771. doi:10.3390/ijms26146771.
31.
DarusmanHSGjeddeASajuthiD, et al. Amyloid beta1-42 and the phoshorylated tau threonine 231 in brains of aged cynomolgus monkeys (Macaca fascicularis). Front Aging Neurosci. 2014;6:313. doi:10.3389/fnagi.2014.00313.
32.
DarusmanHSPandelakiJMulyadiR, et al. Poor memory performance in aged cynomolgus monkeys with hippocampal atrophy, depletion of amyloid beta 1-42 and accumulation of tau proteins in cerebrospinal fluid. In Vivo. 2014;28(2):173-184.
33.
DarusmanHSSajuthiDKalliokoskiO, et al. Correlations between serum levels of beta amyloid, cerebrospinal levels of tau and phospho tau, and delayed response tasks in young and aged cynomolgus monkeys (Macaca fascicularis). J Med Primatol. 2013;42(3):137-146. doi:10.1111/jmp.12044.
34.
DashSParkBKroenkeCDRooneyWDUrbanskiHFKohamaSG.Brain volumetrics across the lifespan of the rhesus macaque. Neurobiol Aging. 2023;126:34-43. doi:10.1016/j.neurobiolaging.2023.02.002.
35.
DattaDLeslieSNWangM, et al. Age-related calcium dysregulation linked with tau pathology and impaired cognition in non-human primates. Alzheimers Dement. 2021;17(6):920-932. doi:10.1002/alz.12325.
36.
DattaDPeroneIWijegunawardanaD, et al. Nanoscale imaging of pT217-tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: evidence of interneuronal trafficking and early-stage neurodegeneration. Alzheimers Dement. 2024;20:2843-2860. doi:10.1002/alz.13737.
37.
Diehl RodriguezRTavaresMCHBruckiSMD, et al. Bearded capuchin monkeys as a model for Alzheimer’s disease. Sci Rep. 2024;14(1):6287. doi:10.1038/s41598-024-56791-y.
38.
DuboisBHampelHFeldmanHH, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292-323. doi:10.1016/j.jalz.2016.02.002.
39.
DumitriuDHaoJHaraY, et al. Selective changes in thin spine density and morphology in monkey prefrontal cortex correlate with aging-related cognitive impairment. J Neurosci. 2010;30(22):7507-7515. doi:10.1523/jneurosci.6410-09.2010.
40.
EdlerMKSherwoodCCMeindlRS, et al. Aged chimpanzees exhibit pathologic hallmarks of Alzheimer’s disease. Neurobiol Aging. 2017;59:107-120. doi:10.1016/j.neurobiolaging.2017.07.006.
41.
FangXTWilliamsGCastnerS, et al. The aging rhesus macaque as a potential model for Alzheimer’s disease/dementia: an in vivo study of [11C]PIB, [11C]UCB-j, [18F]MK-6240 and working memory performance. Alzheimers Dement. 2020;16(S3):e038467. doi:10.1002/alz.038467.
42.
FarrellMEJiangSSchultzAP, et al. Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation. Neurology. 2021;96(4):e619-e631. doi:10.1212/wnl.0000000000011214.
43.
Ferrari-SouzaJPFerreiraPCLBellaverB, et al. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease. Mol Psychiatry. 2022;27(11):4781-4789. doi:10.1038/s41380-022-01716-2.
44.
FerreiraPCLTherriaultJTissotC, et al. Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimers Dement. 2023;19(10):4463-4474. doi:10.1002/alz.13393.
45.
FilshteinTJDuggerBNJinLW, et al. Neuropathological diagnoses of demented Hispanic, Black, and non-Hispanic white decedents seen at an Alzheimer’s disease center. J Alzheimers Dis. 2019;68(1):145-158. doi:10.3233/jad-180992.
46.
Freire-CoboCEdlerMKVargheseM, et al. Comparative neuropathology in aging primates: a perspective. Am J Primatol. 2021;83(11):e23299. doi:10.1002/ajp.23299.
47.
FrostGRLiYM.The role of astrocytes in amyloid production and Alzheimer’s disease. Open Biol. 2017;7(12):170228. doi:10.1098/rsob.170228.
48.
FryeBMCraftSLatimerCS, et al. Aging-related Alzheimer’s disease-like neuropathology and functional decline in captive vervet monkeys (Chlorocebus aethiops sabaeus). Am J Primatol. 2021;83(11):e23260. doi:10.1002/ajp.23260.
49.
FryeBMNegreyJDJohnsonCSC, et al. Mediterranean diet protects against a neuroinflammatory cortical transcriptome: associations with brain volumetrics, peripheral inflammation, social isolation, and anxiety in nonhuman primates (Macaca fascicularis). Brain Behav Immun. 2024;119:681-692. doi:10.1016/j.bbi.2024.04.016.
50.
FryeBMValurePMCraftS, et al. Temporal emergence of age-associated changes in cognitive and physical function in vervets (Chlorocebus aethiops sabaeus). Geroscience. 2021;43(3):1303-1315. doi:10.1007/s11357-021-00338-w.
51.
FukuyamaRMizunoTMoriSNakajimaKFushikiSYanagisawaK.Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer’s disease patients. Eur Neurol. 2000;43(3):155-160. doi:10.1159/000008156.
52.
GearingMTiggesJMoriHMirraSS.Beta-Amyloid (A beta) deposition in the brains of aged orangutans. Neurobiol Aging. 1997;18(2):139-146. doi:10.1016/s0197-4580(97)00012-2.
53.
GiannakopoulosPSilholSJallageasV, et al. Quantitative analysis of tau protein-immunoreactive accumulations and beta amyloid protein deposits in the cerebral cortex of the mouse lemur, microcebus murinus. Acta Neuropathol. 1997;94(2):131-139. doi:10.1007/s004010050684.
54.
HamelinLLagardeJDorothéeG, et al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer’s disease. Brain. 2018;141(6):1855-1870. doi:10.1093/brain/awy079.
55.
HampelHMesulamMMCuelloAC, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018;141(7):1917-1933. doi:10.1093/brain/awy132.
56.
HaraYRappPRMorrisonJH.Neuronal and morphological bases of cognitive decline in aged rhesus monkeys. Age. 2012;34(5):1051-1073. doi:10.1007/s11357-011-9278-5.
57.
HärtigWBrücknerGSchmidtC, et al. Co-localization of beta-amyloid peptides, apolipoprotein E and glial markers in senile plaques in the prefrontal cortex of old rhesus monkeys. Brain Res. 1997;751(2):315-322. doi:10.1016/s0006-8993(96)01423-0.
58.
HeuerEJacobsJDuR, et al. Amyloid-related imaging abnormalities in an aged squirrel monkey with cerebral amyloid angiopathy. J Alzheimers Dis. 2017;57(2):519-530. doi:10.3233/jad-160981.
59.
HorieKSalvadóGBarthélemyNR, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. Nat Med. 2023;29(8):1954-1963. doi:10.1038/s41591-023-02443-z.
60.
HostetlerEDWaljiAMZengZ, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57(10):1599-1606. doi:10.2967/jnumed.115.171678.
61.
HuYFryattGLGhorbaniM, et al. Replicative senescence dictates the emergence of disease-associated microglia and contributes to Aβ pathology. Cell Rep. 2021;35(10):109228. doi:10.1016/j.celrep.2021.109228.
62.
HuangXHuangSFuFSongJZhangYYueF.Characterization of preclinical Alzheimer’s disease model: spontaneous type 2 diabetic cynomolgus monkeys with systemic pro-inflammation, positive biomarkers and developing AD-like pathology. Alzheimers Res Ther. 2024;16(1):52. doi:10.1186/s13195-024-01416-9.
63.
HymanBTPhelpsCHBeachTG, et al. National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1-13. doi:10.1016/j.jalz.2011.10.007.
64.
IkonomovicMDBuckleyCJAbrahamsonEE, et al. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer’s disease. Acta Neuropathol. 2020;140(4):463-476. doi:10.1007/s00401-020-02175-1.
65.
IkonomovicMDKlunkWEAbrahamsonEE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 2008;131(pt 6):1630-1645. doi:10.1093/brain/awn016.
66.
InoueYShueFBuGKanekiyoT.Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease. Mol Neurodegener. 2023;18(1):46. doi:10.1186/s13024-023-00640-5.
67.
IqbalK.Tau and Alzheimer’s disease: past, present and future. Cytoskeleton. 2024;81(1):116-121. doi:10.1002/cm.21822.
68.
IsidroF.Brain aging and Alzheimer’s disease, a perspective from non-human primates. Aging. 2024;16(20):13145-13171. doi:10.18632/aging.206143.
69.
IwaideSNakayamaYChambersJK, et al. Senile plaques and phosphorylated tau deposition in a super-aged rhesus monkey (Macaca mulatta). J Vet Med Sci. 2023;85(12):1296-1300. doi:10.1292/jvms.23-0313.
70.
JackCRJr.Advances in Alzheimer’s disease research over the past two decades. Lancet Neurol. 2022;21(10):866-869. doi:10.1016/s1474-4422(22)00298-8.
71.
JackCRJrAndrewsJSBeachTG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s association workgroup. Alzheimers Dement. 2024;20(8):5143-5169. doi:10.1002/alz.13859.
72.
JackCRJrBennettDABlennowK, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018.
73.
JackCRJrPetersenRCO’BrienPCTangalosEG.MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology. 1992;42(1):183-188. doi:10.1212/wnl.42.1.183.
74.
JackCRJrWisteHJAlgeciras-SchimnichA, et al. Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain. 2023;146(5):2029-2044. doi:10.1093/brain/awad042.
75.
JackCRJrWisteHJWeigandSD, et al. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017;16(6):435-444. doi:10.1016/s1474-4422(17)30077-7.
76.
JanelidzeSMattssonNPalmqvistS, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med. 2020;26(3):379-386. doi:10.1038/s41591-020-0755-1.
77.
JellingerKAAttemsJ.Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm. 2015;122(4):505-521. doi:10.1007/s00702-014-1288-x.
78.
JesterHMGosraniSPDingHZhouXKoMCMaT.Characterization of early Alzheimer’s disease-like pathological alterations in non-human primates with aging: a pilot study. J Alzheimers Dis. 2022;88(3):957-970. doi:10.3233/jad-215303.
79.
KalininSWillardSLShivelyCA, et al. Development of amyloid burden in African green monkeys. Neurobiol Aging. 2013;34(10):2361-2369. doi:10.1016/j.neurobiolaging.2013.03.023.
80.
KamphuisWMiddeldorpJKooijmanL, et al. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer’s disease. Neurobiol Aging. 2014;35(3):492-510. doi:10.1016/j.neurobiolaging.2013.09.035.
81.
KeukerJILuitenPGFuchsE.Preservation of hippocampal neuron numbers in aged rhesus monkeys. Neurobiol Aging. 2003;24(1):157-165. doi:10.1016/s0197-4580(02)00062-3.
82.
KodamaRYangXSaskiY, et al. Age-related lesions in the cerebrum in middle-aged female cynomolgus monkeys. Toxicol Pathol. 2010;38(2):303-311. doi:10.1177/0192623309358904.
83.
KoratŠBidesiNSRBonannoF, et al. Alpha-synuclein PET tracer development-an overview about current efforts. Pharmaceuticals. 2021;14(9):847. doi:10.3390/ph14090847.
84.
KrizanISolingapuram SaiKKDamukaN, et al. Exploratory dual PET imaging of [(18)F] fluorodeoxyglucose and [(11)C]acetoacetate in type 2 diabetic nonhuman primates. Bioorg Med Chem Lett. 2024;111:129906. doi:10.1016/j.bmcl.2024.129906.
85.
KyleCTStokesJBennettJ, et al. Cytoarchitectonically-driven MRI atlas of nonhuman primate hippocampus: preservation of subfield volumes in aging. Hippocampus. 2019;29(5):409-421. doi:10.1002/hipo.22809.
86.
La JoieRAyaktaNSeeleyWW, et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 2019;15(2):205-216. doi:10.1016/j.jalz.2018.09.001.
87.
LaiZCMossMBKillianyRJRoseneDLHerndonJG.Executive system dysfunction in the aged monkey: spatial and object reversal learning. Neurobiol Aging. 1995;16(6):947-954. doi:10.1016/0197-4580(95)02014-4.
88.
LatimerCSShivelyCAKeeneCD, et al. A nonhuman primate model of early Alzheimer’s disease pathologic change: implications for disease pathogenesis. Alzheimers Dement. 2019;15(1):93-105. doi:10.1016/j.jalz.2018.06.3057.
89.
LeslieSNKanyoJDattaD, et al. Simple, single-shot phosphoproteomic analysis of heat-stable tau identifies age-related changes in pS235- and pS396-tau levels in non-human primates. Front Aging Neurosci. 2021;13:767322. doi:10.3389/fnagi.2021.767322.
90.
LevinFDyrbaMTeipelSJGrotheMJ.Hypometabolic subtypes of AD are linked to comorbid hippocampal sclerosis and Lewy body pathology. Alzheimers Res Ther. 2025;17(1):172. doi:10.1186/s13195-025-01796-6.
91.
LiuYJZhaoJYHanWW, et al. Microvascular burden and long-term risk of stroke and dementia in type 2 diabetes mellitus. J Affect Disord. 2024;354:68-74. doi:10.1016/j.jad.2024.03.053.
92.
LivingstonGHuntleyJLiuKY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing commission. Lancet. 2024;404(10452):572-628. doi:10.1016/s0140-6736(24)01296-0.
93.
LombardiGPancaniSMancaR, et al. Role of blood P-tau isoforms (181, 217, 231) in predicting conversion from MCI to dementia due to Alzheimer’s disease: a review and meta-analysis. Int J Mol Sci. 2024;25(23):12916. doi:10.3390/ijms252312916.
94.
LoweVJCurranGFangP, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58. doi:10.1186/s40478-016-0315-6.
95.
LoweVJLundtESAlbertsonSM, et al. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimers Dement. 2019;15(7):927-939. doi:10.1016/j.jalz.2019.03.016.
96.
MacedoACTissotCTherriaultJ, et al. The use of tau PET to stage Alzheimer disease according to the Braak staging framework. J Nucl Med. 2023;64(8):1171-1178. doi:10.2967/jnumed.122.265200.
97.
Maldonado-DíazCHiyaSYokodaRT, et al. Disentangling and quantifying the relative cognitive impact of concurrent mixed neurodegenerative pathologies. Acta Neuropathol. 2024;147(1):58. doi:10.1007/s00401-024-02716-y.
98.
MatsuoESShinRWBillingsleyML, et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau. Neuron. 1994;13(4):989-1002. doi:10.1016/0896-6273(94)90264-x.
99.
MeccaAPChenMKO’DellRS, et al. In vivo measurement of widespread synaptic loss in Alzheimer’s disease with SV2A PET. Alzheimers Dement. 2020;16(7):974-982. doi:10.1002/alz.12097.
100.
MendesAJRibaldiFLathuiliereA, et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol. 2024;271(4):2053-2066. doi:10.1007/s00415-023-12148-5.
101.
MetzlerLAPMetzgerJMGerredKJEmborgMEKapoorA. Expression patterns of blood-based biomarkers of neurodegeneration and inflammation across adulthood in rhesus macaques. Exp Gerontol. 2025;203:112736. doi:10.1016/j.exger.2025.112736.
102.
Milà-AlomàMAshtonNJShekariM, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease. Nat Med. 2022;28(9):1797-1801. doi:10.1038/s41591-022-01925-w.
103.
MirraSSHartMNTerryRD.Making the diagnosis of Alzheimer’s disease. A primer for practicing pathologists. Arch Pathol Lab Med. 1993;117(2):132-144.
104.
MoloneyCMLabuzanSACrookJE, et al. Phosphorylated tau sites that are elevated in Alzheimer’s disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain. Alzheimers Dement. 2022;19:1029-1040. doi:10.1002/alz.12749.
105.
MoloneyCMLoweVJMurrayME.Visualization of neurofibrillary tangle maturity in Alzheimer’s disease: a clinicopathologic perspective for biomarker research. Alzheimers Dement. 2021;17(9):1554-1574. doi:10.1002/alz.12321.
106.
MontineTJPhelpsCHBeachTG, et al. National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012;123(1):1-11. doi:10.1007/s00401-011-0910-3.
107.
Montoliu-GayaLBenedetALTissotC, et al. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat Aging. 2023;3(6):661-669. doi:10.1038/s43587-023-00405-1.
108.
MooreTLKillianyRJHerndonJGRoseneDLMossMB.Executive system dysfunction occurs as early as middle-age in the rhesus monkey. Neurobiol Aging. 2006;27(10):1484-1493. doi:10.1016/j.neurobiolaging.2005.08.004.
109.
MrdjenDAmouzgarMCannonB, et al. Spatial proteomics reveals human microglial states shaped by anatomy and neuropathology [published online ahead of print June 2, 2023]. Res Sq. doi:10.21203/rs.3.rs-2987263/v1.
110.
NakamuraSNakayamaHGotoNOnoFSakakibaraIYoshikawaY.Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys. J Med Primatol. 1998;27(5):244-252.
111.
Ndung’uMHärtigWWegnerF, et al. Cerebral amyloid β(42) deposits and microvascular pathology in ageing baboons. Neuropathol Appl Neurobiol. 2012;38(5):487-499. doi:10.1111/j.1365-2990.2011.01246.x.
112.
NishiyamaSOhbaHKanazawaMKakiuchiTTsukadaH.Comparing α7 nicotinic acetylcholine receptor binding, amyloid-β deposition, and mitochondria complex-I function in living brain: a PET study in aged monkeys. Synapse. 2015;69(10):475-483. doi:10.1002/syn.21842.
113.
NodaAMurakamiYNishiyamaS, et al. Amyloid imaging in aged and young macaques with [11C]PIB and [18F]FDDNP. Synapse. 2008;62(6):472-475. doi:10.1002/syn.20508.
114.
OgrodnikMEvansSAFielderE, et al. Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice. Aging Cell. 2021;20(2):e13296. doi:10.1111/acel.13296.
115.
ParnettiLChipiESalvadoriND’AndreaKEusebiP.Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis. Alzheimers Res Ther. 2019;11(1):7. doi:10.1186/s13195-018-0459-7.
116.
PascoalTABenedetALAshtonNJ, et al. Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27(9):1592-1599. doi:10.1038/s41591-021-01456-w.
117.
PaspalasCDCarlyleBCLeslieS, et al. The aged rhesus macaque manifests Braak stage III/IV Alzheimer’s-like pathology. Alzheimers Dement. 2018;14(5):680-691. doi:10.1016/j.jalz.2017.11.005.
118.
PawlikMFuchsEWalkerLCLevyE.Primate-like amyloid-beta sequence but no cerebral amyloidosis in aged tree shrews. Neurobiol Aging. 1999;20(1):47-51. doi:10.1016/s0197-4580(99)00017-2.
119.
PereiraJBJanelidzeSSmithR, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease. Brain. 2021;144(11):3505-3516. doi:10.1093/brain/awab223.
120.
Perez-CruzCRodriguez-CallejasJD.The common marmoset as a model of neurodegeneration. Trends Neurosci. 2023;46(5):394-409. doi:10.1016/j.tins.2023.02.002.
121.
PerezSERaghantiMAHofPR, et al. Alzheimer’s disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla). J Comp Neurol. 2013;521(18):4318-4338. doi:10.1002/cne.23428.
122.
PetersA.Structural changes that occur during normal aging of primate cerebral hemispheres. Neurosci Biobehav Rev. 2002;26(7):733-741. doi:10.1016/s0149-7634(02)00060-x.
123.
PetersARoseneDLMossMB, et al. Neurobiological bases of age-related cognitive decline in the rhesus monkey. J Neuropathol Exp Neurol. 1996;55(8):861-874. doi:10.1097/00005072-199608000-00001.
124.
PillaiJABonner-JacksonABekrisLMSafarJBenaJLeverenzJB.Highly elevated cerebrospinal fluid total tau level reflects higher likelihood of non-amnestic subtype of Alzheimer’s disease. J Alzheimers Dis. 2019;70(4):1051-1058. doi:10.3233/jad-190519.
125.
RafiiMSAisenPS.Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2025;21:490-498. doi:10.1038/s41582-025-01123-5.
126.
RobertsonELBoehnkeSELyraESNM, et al. Characterization of cerebrospinal fluid biomarkers associated with neurodegenerative diseases in healthy cynomolgus and rhesus macaque monkeys. Alzheimers Dement. 2022;8(1):e12289. doi:10.1002/trc2.12289.
127.
RosenRFFarbergASGearingM, et al. Tauopathy with paired helical filaments in an aged chimpanzee. J Comp Neurol. 2008;509(3):259-270. doi:10.1002/cne.21744.
128.
RosenRFWalkerLCLevineH 3rd. PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer’s disease. Neurobiol Aging. 2011;32(2):223-234. doi:10.1016/j.neurobiolaging.2009.02.011.
129.
SchindlerSEBollingerJGOvodV, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647-e1659. doi:10.1212/wnl.0000000000008081.
130.
SelkoeDJHardyJ.The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595-608. doi:10.15252/emmm.201606210.
131.
SeoSWAyaktaNGrinbergLT, et al. Regional correlations between [(11)C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. Neuroimage Clin. 2017;13:130-137. doi:10.1016/j.nicl.2016.11.008.
132.
SiddiqiZKemperTLKillianyR.Age-related neuronal loss from the substantia nigra-pars compacta and ventral tegmental area of the rhesus monkey. J Neuropathol Exp Neurol. 1999;58(9):959-971. doi:10.1097/00005072-199909000-00006.
133.
SmithDERappPRMcKayHMRobertsJATuszynskiMH.Memory impairment in aged primates is associated with focal death of cortical neurons and atrophy of subcortical neurons. J Neurosci. 2004;24(18):4373-4381. doi:10.1523/jneurosci.4289-03.2004.
134.
SperlingRAAisenPSBeckettLA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280-292. doi:10.1016/j.jalz.2011.03.003.
135.
StonebargerGABimonte-NelsonHAUrbanskiHF.The rhesus macaque as a translational model for neurodegeneration and Alzheimer’s disease. Front Aging Neurosci. 2021;13:734173. doi:10.3389/fnagi.2021.734173.
136.
StonebargerGAUrbanskiHFWoltjerRL, et al. Amyloidosis increase is not attenuated by long-term calorie restriction or related to neuron density in the prefrontal cortex of extremely aged rhesus macaques. Geroscience. 2020;42(6):1733-1749. doi:10.1007/s11357-020-00259-0.
137.
Suárez-CalvetMMorenas-RodríguezEKleinbergerG, et al. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Mol Neurodegener. 2019;14(1):1. doi:10.1186/s13024-018-0301-5.
138.
TaoXHeJZhangY, et al. Fluid biomarkers of vascular cognitive Impairment: from vascular pathophysiology to potential clinical applications. Neuroscience. 2025;579:267-283. doi:10.1016/j.neuroscience.2025.06.018.
139.
ThalDRRubUOrantesMBraakH.Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-1800. doi:10.1212/wnl.58.12.1791.
140.
ThomasJLNilaverBILomnicziA, et al. Pathological markers of Alzheimer’s disease and related dementia in the rhesus macaque amygdala. J Alzheimers Dis Rep. 2024;8(1):25-32. doi:10.3233/adr-230184.
141.
TianYECropleyVMaierABLautenschlagerNTBreakspearMZaleskyA.Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality. Nat Med. 2023;29(5):1221-1231. doi:10.1038/s41591-023-02296-6.
142.
UemuraE.Age-related changes in the subiculum of Macaca mulatta: synaptic density. Exp Neurol. 1985;87(3):403-411. doi:10.1016/0014-4886(85)90171-2.
143.
UnoHAlsumPBDongS, et al. Cerebral amyloid angiopathy and plaques, and visceral amyloidosis in aged macaques. Neurobiol Aging. 1996;17(2):275-281. doi:10.1016/0197-4580(95)02063-2.
144.
VassilakiMAakreJAMielkeMM, et al. Multimorbidity and neuroimaging biomarkers among cognitively normal persons. Neurology. 2016;86(22):2077-2084. doi:10.1212/wnl.0000000000002624.
145.
VemuriPGraff-RadfordJLesnickTG, et al. White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. Brain Commun. 2021;3(2):fcab076. doi:10.1093/braincomms/fcab076.
146.
VillemagneVLHaradaRDoréV, et al. Assessing reactive astrogliosis with (18)F-SMBT-1 across the Alzheimer disease spectrum. J Nucl Med. 2022;63(10):1560-1569. doi:10.2967/jnumed.121.263255.
147.
WalkerLC.Animal models of cerebral beta-amyloid angiopathy. Brain Res Brain Res Rev. 1997;25(1):70-84. doi:10.1016/s0165-0173(97)00017-9.
148.
WalkerLCJuckerM.The exceptional vulnerability of humans to Alzheimer’s disease. Trends Mol Med. 2017;23(6):534-545. doi:10.1016/j.molmed.2017.04.001.
149.
WangJSunXYinYCaoR.Longitudinal decline in striatal DAT binding in LRRK2 Parkinson’s disease: connections with CSF α-synuclein seeding activity. J Neurol. 2025;272(9):630. doi:10.1007/s00415-025-13359-8.
150.
WardRJZuccaFADuynJHCrichtonRRZeccaL.The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045-1060. doi:10.1016/s1474-4422(14)70117-6.
151.
WardlawJMSmithEEBiesselsGJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838. doi:10.1016/s1474-4422(13)70124-8.
152.
WesselingHMairWKumarM, et al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer’s disease. Cell. 2020;183(6):1699e13-161713. doi:10.1016/j.cell.2020.10.029.
153.
YueFLuCAiYChanPZhangZ.Age-associated changes of cerebrospinal fluid amyloid-beta and tau in cynomolgus monkeys. Neurobiol Aging. 2014;35(7):1656-1659. doi:10.1016/j.neurobiolaging.2014.01.139.
154.
ZeamerADecampEClarkKSchneiderJS.Attention, executive functioning and memory in normal aged rhesus monkeys. Behav Brain Res. 2011;219(1):23-30. doi:10.1016/j.bbr.2010.12.021.
155.
ZeissCJHuttnerANairnAC, et al. The neuropathologic basis for translational biomarker development in the macaque model of late-onset Alzheimer’s disease. J Alzheimers Dis. 2025;104(4):1243-1258. doi:10.1177/13872877251323787.
156.
ZhangXZhangRRaabS, et al. Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. Circulation. 2011;124(1):77-86. doi:10.1161/circulationaha.110.990333.
157.
ZhouRJiBKongY, et al. PET imaging of neuroinflammation in Alzheimer’s disease. Front Immunol. 2021;12:739130. doi:10.3389/fimmu.2021.739130.
